We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Screening Test Detects Chlamydial Infection

By LabMedica International staff writers
Posted on 26 Mar 2013
A rapid nonculture method for detection of Chlamydia trachomatis has been developed based on the measurement of specific enzymatic activity in urogenital tract specimens.

The method is based on the level of the activity of α-mannosidase, a gylcoside hydrolase involved in the maturation and degradation of glycoprotein-linked oligosaccharides, on its specific chromogen. More...


Scientists at Zhengzhou University (China) evaluated the performance of a method, which measured the α-mannosidase activities of C. trachomatis serotype D strain and 29 standard strains related to clinical urogenital pathogens. They also assayed 553 urogenital tract specimens via cell culture method and ligase chain reaction method (LCR), adopting an expanded gold standard.

For the 203 male cases, three urethral discharge specimens from 151 outpatients or three prostate massage liquid specimens from 52 outpatients were collected with sterile rayon swabs. For the 350 female cases, three cervical secretion specimens were collected from 232 outpatients, or three vaginal secretion specimens were collected from 118 outpatients, with sterile rayon swabs using vaginal forceps.

The enzymatic method was based on the substrate 6-chloro-3-indolyl-α-D-mannoside and the chromogenic reagent contained fast violet B salt (J&K Chemical; Shanghai, China; www.jkchemical.com). The result was considered to be positive when the optical density (OD) at 512 nm was greater than 0.150, if the color changed from colorless to red or brown after 15 minutes of incubation at 37 °C. Cell culture and LCR method were used to evaluate the clinical performance of the enzymatic method.

Of the 553 clinical samples, 132 samples were positive with the OD ranging from 0.161 to 1.955, and 421 samples were negative with OD ranging from 0.013 to 0.142. The sensitivity of the enzymatic method was 91.5%, and the specificity of this method was 90.0%.

The authors concluded that they had demonstrated that there were no significant differences between the enzymatic method and the reference method if prostate specimens were excluded. Therefore, α-D-mannosidase activity may be a useful marker for C. trachomatis in urogenital tract specimens, with many advantages, such as its speed, ease of use, convenience, and specialized equipment is not essential. The study was published on January 24, 2013, in, the BioMed Central journal BMC Infectious Diseases.

Related Links:

Zhengzhou University
J&K Chemical



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Electrolyte Analyzer
BKE-B
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.